Results of Operations and Financial Condition. On August 5, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Regulation FD Disclosure . On June 22, 2026, LifeMD, Inc. (the “Company” or “LifeMD”) announced a strategic co-marketing collaboration supporting a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The program will launch in July 2026 and will initially be available in 37 states. The Company entered into a Master Services Agreement and Statement of Work, as well as Specialty Pharmacy S…

Results of Operations and Financial Condition. On May 6, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

CFO — Marc Benathen: Mr. Benathen is departing to pursue a new opportunity.

Results of Operations and Financial Condition. On March 9, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025, and its earnings guidance for 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Regulation FD Disclosure. On January 6, 2026, the Company issued a press release announcing the Credit Facility. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the press r…

Entry into a Material Definitive Agreement. On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”) to support potential corporate development and/or shareholder value creation initiatives. The Credit Facility may be increased in the aggregate principal amoun…

Results of Operations and Financial Condition. On November 17, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing und…

of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward Looking Statements This filing includes forward-looking statements w…

of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing. Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this repor…

Completion of Acquisition or Disposition of Assets. The information set forth in

Entry into a Material Definitive Agreement. On November 4, 2025, LifeMD, Inc., a Delaware corporation (“LifeMD”), entered into and simultaneously consummated the closing of a Stock Purchase Agreement (the “Purchase Agreement”) by and among LifeMD, Inc., as a Seller and Seller Representative and the other seller parties thereto (collectively, the “Sellers”), WorkSimpli Software LLC, a Puerto Rico limited liability company (the “Company”), and Lion Buyer, LLC, a Delaware limited liability compa…

Changes in Registrant’s Certifying Accountant. Dismissal of Independent Registered Public Accounting Firm On August 15, 2025, LifeMD, Inc. (the “Company”), with the approval of the Audit Committee of the Company’s Board of Directors, dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm. As previously disclosed in a Current Report on Form 8-K filed on April 25, 2025, on April 24, 2025 Marcum LLP was dismissed, and CBIZ CPAs was appointed, as the…

Results of Operations and Financial Condition. On August 5, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Se…

Chief Operating Officer — Shayna Webb Dray: Shayna Webb Dray was promoted to Chief Operating Officer from Senior Vice President of Operations.

Results of Operations and Financial Condition. On May 6, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities A…

Regulation FD Disclosure . On April 25, 2025, LifeMD, Inc. (the “Company”), entered into and closed on an Asset Purchase Agreement (the “Purchase Agreement”), by and among the Company; OHHMD, PLLC (“Seller”), a North Carolina professional limited liability company; Doug Lucas, DO, the sole member of OHHMD; and the Company’s affiliate LifeMD Southern Patient Medical Care, P.C., a Florida professional corporation (“PC Purchaser”). Pursuant to the Purchase Agreement, the Company acquired key ass…

Changes in Registrant’s Certifying Accountant. On April 24, 2025 Marcum LLP (“Marcum”), which served as the independent registered public accounting firm of LifeMD, Inc. (the “Company”, “we”, “our”) since 2022, informed the Company that Marcum resigned as the Company’s independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum. On April 24, 2025 the Company and with the approval of the Audit Committee of the Company’s Board of Dir…

Results of Operations and Financial Condition. On March 10, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three months and year ended December 31, 2024, and its earnings guidance for 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporate…

The filing describes a compensation amendment for the CEO, not a management change.

Director — Robert Jindal: Robert Jindal voluntarily resigned from his position as a member of the board of directors.

Director — Naveen Bhatia: Mr. Naveen Bhatia voluntarily resigned from his position as a member of the board of directors.

The filing describes a stockholder approval of an equity and incentive plan amendment, not a management change.

Director — Calum MacRae: Dr. Calum MacRae was appointed to the Board of Directors and received equity grants.